PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon

Bayer

Status: Completed

Conditions: Multiple Sclerosis

Treatments: Drug: Betaferon, BAY86-5046; Other: PEAK; Device: BETACONNECT; Other: myBETAapp

Study type: Observational

Funder types: Industry

Identifiers

NCT03808142

20263

Details and patient eligibility

About

In this study researchers wanted to learn more about the medication usage behavior among multiple sclerosis (MS) patients treated with Betaferon using the myBETAapp which includes the elements to what extent

• taking medication matched the presciber´s recommendation (adherence, compliance),
• treatment for the prescribed duration (persistence) was continued and
• injections were missed. Among MS patients treated with Betaferon using the myBETAapp the study also collected information on the health-related quality of life, treatment satisfaction and satisfaction with treatment support.

Full description

The PROmyBETAappGame study was a mixed prospective and retrospective, non-interventional, observational cohort study

Enrollment: 79 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

• Patients aged ≥ 18 years.
• Patients on treatment with Betaferon (every Betaferon box contains a "Mixject" number, which is a product specific number unrelated to the study. Only patients prescribed Betaferon for their MS will be able to use the myBETAapp and participate in the study).
• Patients must be using the myBETAapp.
• Electronic informed consent must be obtained.

Exclusion criteria

• No exclusion criteria for participation in this study were defined.

Trial design

79 participants in 1 patient group

Treatment

Description:

During a 3-months period all patients with an active myBETAapp account were invited to participate in the study (3-month invitation period=enrollment period). Patients seek more information about the study were able to access a detailed informed consent form via their app providing step-by-step background information. Those patients were wishing to participate in the study were able to provide (electronic) informed consent (ICF).

Treatment:

Other: PEAK

Device: BETACONNECT

Other: myBETAapp

Drug: Betaferon, BAY86-5046